Latest News

2 Years of Treatment With Dupilumab Led to Improvements In Symptoms of AD and Comorbid Anxiety, Depression
2 Years of Treatment With Dupilumab Led to Improvements In Symptoms of AD and Comorbid Anxiety, Depression

May 7th 2024

Following treatment, 17.5% and 13% of patients reported residual depressive and anxiety symptoms.

New Eblasakimab Data Shows Promise for Patients With AD and Inadequate Response to Dupilumab
New Eblasakimab Data Shows Promise for Patients With AD and Inadequate Response to Dupilumab

May 7th 2024

Supporting Patients With AD and Their Caregivers: Insights from Argentina
Supporting Patients With AD and Their Caregivers: Insights from Argentina

May 2nd 2024

More News

© 2024 MJH Life Sciences

All rights reserved.